Gossamer Bio to Report Q1 2026 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy GOSS?
Source: Newsfilter
- Earnings Release Announcement: Gossamer Bio has announced that it will report its Q1 2026 financial results on May 18, 2026, indicating ongoing progress in the treatment of pulmonary arterial hypertension, which is expected to provide investors with critical financial data and business updates.
- Management Conference Call: Following the earnings release, the management team will host a conference call and webcast at 8:00 a.m. ET on May 18, 2026, aimed at discussing the financial results in detail and providing the latest corporate updates to enhance investor confidence.
- Dial-in Information: The domestic dial-in number is 1-800-715-9871, while the international dial-in number is 1-646-307-1963, with Conference ID 3974570, ensuring investors can easily participate in the discussion and improve transparency.
- Webcast Replay Availability: An audio replay of the conference will be available for 30 days on the company's investor section of the website, further enhancing information accessibility and helping investors stay informed about the company's developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.330
Low
10.00
Averages
12.33
High
15.00
Current: 0.330
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio to Report Q1 2026 Financial Results
- Earnings Release Announcement: Gossamer Bio has announced that it will report its Q1 2026 financial results on May 18, 2026, indicating ongoing progress in the treatment of pulmonary arterial hypertension, which is expected to provide investors with critical financial data and business updates.
- Management Conference Call: Following the earnings release, the management team will host a conference call and webcast at 8:00 a.m. ET on May 18, 2026, aimed at discussing the financial results in detail and providing the latest corporate updates to enhance investor confidence.
- Dial-in Information: The domestic dial-in number is 1-800-715-9871, while the international dial-in number is 1-646-307-1963, with Conference ID 3974570, ensuring investors can easily participate in the discussion and improve transparency.
- Webcast Replay Availability: An audio replay of the conference will be available for 30 days on the company's investor section of the website, further enhancing information accessibility and helping investors stay informed about the company's developments.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the trial failure announcement, Gossamer's stock price plummeted by 80%, reflecting extreme market pessimism regarding its future prospects and severely undermining investor confidence in the company's management.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, which may have led to significant investor losses, highlighting the potential reputational risks for the company.
- Listing Risks: On April 9, 2026, Gossamer revealed that it had not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, which could lead to delisting risks and further exacerbate investor concerns.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ:GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence, which may lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, could result in broader legal liabilities for the company.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, highlighting the company's lack of transparency in disclosures, which could impact its future fundraising capabilities and market reputation.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Gossamer Bio and certain executives, alleging violations of federal securities laws on behalf of investors who purchased shares between June 16, 2025, and February 20, 2026, seeking to recover damages.
- Allegations of Misrepresentation: The complaint claims that the defendants misled investors by promoting positive results from the Phase 3 PROSERA study while concealing significant adverse facts regarding the study's design, particularly the failure to adequately control for placebo responses at Latin American sites, which inflated the stock prices.
- Investor Participation Opportunity: Affected investors have until June 1, 2026, to request to be appointed as lead plaintiff in the case, allowing them to participate in any recovery without needing to serve as lead plaintiff.
- No-Cost Representation: The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they successfully recover funds for investors, minimizing financial risk for those involved in the lawsuit.
See More
Faruqi & Faruqi Investigates Gossamer Investor Claims
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Gossamer Bio, Inc., focusing on investors who purchased securities between June 16, 2025, and February 20, 2026, indicating possible legal risks for the company.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310), aiming to assist investors in understanding their legal rights.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Gossamer is June 1, 2026, which may impact their ability to file claims.
- Legal Risk Advisory: The initiation of this investigation and class action could negatively affect Gossamer's stock price, prompting investors to closely monitor developments to take necessary legal actions promptly.
See More
Gossamer Bio Securities Class Action Notice
- Class Action Deadline: Purchasers of Gossamer Bio, Inc. (NASDAQ: GOSS) securities are reminded that the lead plaintiff deadline for the class action is June 1, 2026, and missing this date will prevent participation in potential compensation, impacting investor rights.
- No Out-of-Pocket Fees: Investors can seek compensation through the class action without any upfront costs, which reduces financial risk for investors and encourages more affected parties to join the lawsuit.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and enhancing investor confidence in their representation.
- Case Details Disclosure: The lawsuit alleges that defendants made false and misleading statements regarding Gossamer's PROSERA study, leading to investor losses when the true information was revealed, underscoring the importance of transparency and accurate disclosures.
See More
Gossamer Bio to Report Q1 2026 Financial Results
- Earnings Release Announcement: Gossamer Bio has announced that it will report its Q1 2026 financial results on May 18, 2026, indicating ongoing progress in the treatment of pulmonary arterial hypertension, which is expected to provide investors with critical financial data and business updates.
- Management Conference Call: Following the earnings release, the management team will host a conference call and webcast at 8:00 a.m. ET on May 18, 2026, aimed at discussing the financial results in detail and providing the latest corporate updates to enhance investor confidence.
- Dial-in Information: The domestic dial-in number is 1-800-715-9871, while the international dial-in number is 1-646-307-1963, with Conference ID 3974570, ensuring investors can easily participate in the discussion and improve transparency.
- Webcast Replay Availability: An audio replay of the conference will be available for 30 days on the company's investor section of the website, further enhancing information accessibility and helping investors stay informed about the company's developments.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the trial failure announcement, Gossamer's stock price plummeted by 80%, reflecting extreme market pessimism regarding its future prospects and severely undermining investor confidence in the company's management.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, which may have led to significant investor losses, highlighting the potential reputational risks for the company.
- Listing Risks: On April 9, 2026, Gossamer revealed that it had not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, which could lead to delisting risks and further exacerbate investor concerns.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ:GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence, which may lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, could result in broader legal liabilities for the company.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, highlighting the company's lack of transparency in disclosures, which could impact its future fundraising capabilities and market reputation.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Gossamer Bio and certain executives, alleging violations of federal securities laws on behalf of investors who purchased shares between June 16, 2025, and February 20, 2026, seeking to recover damages.
- Allegations of Misrepresentation: The complaint claims that the defendants misled investors by promoting positive results from the Phase 3 PROSERA study while concealing significant adverse facts regarding the study's design, particularly the failure to adequately control for placebo responses at Latin American sites, which inflated the stock prices.
- Investor Participation Opportunity: Affected investors have until June 1, 2026, to request to be appointed as lead plaintiff in the case, allowing them to participate in any recovery without needing to serve as lead plaintiff.
- No-Cost Representation: The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they successfully recover funds for investors, minimizing financial risk for those involved in the lawsuit.
See More
Faruqi & Faruqi Investigates Gossamer Investor Claims
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Gossamer Bio, Inc., focusing on investors who purchased securities between June 16, 2025, and February 20, 2026, indicating possible legal risks for the company.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310), aiming to assist investors in understanding their legal rights.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Gossamer is June 1, 2026, which may impact their ability to file claims.
- Legal Risk Advisory: The initiation of this investigation and class action could negatively affect Gossamer's stock price, prompting investors to closely monitor developments to take necessary legal actions promptly.
See More
Gossamer Bio Securities Class Action Notice
- Class Action Deadline: Purchasers of Gossamer Bio, Inc. (NASDAQ: GOSS) securities are reminded that the lead plaintiff deadline for the class action is June 1, 2026, and missing this date will prevent participation in potential compensation, impacting investor rights.
- No Out-of-Pocket Fees: Investors can seek compensation through the class action without any upfront costs, which reduces financial risk for investors and encourages more affected parties to join the lawsuit.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and enhancing investor confidence in their representation.
- Case Details Disclosure: The lawsuit alleges that defendants made false and misleading statements regarding Gossamer's PROSERA study, leading to investor losses when the true information was revealed, underscoring the importance of transparency and accurate disclosures.
See More
